Beijing Ophthalmology and Visual Sciences Key Lab, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
BMC Ophthalmol. 2024 Oct 31;24(1):476. doi: 10.1186/s12886-024-03740-y.
To assess the long-term outcomes of patients with glaucoma secondary to iridocorneal endothelial syndrome (GS-ICE) who underwent Ahmed glaucoma valve (AGV) implantation combined with phacoemulsification and intraocular lens (IOL) implantation surgery.
In this non-comparative retrospective case series study, twelve patients with uncontrolled GS-ICE and cataract underwent Ahmed aqueous shunt combined with phacoemulsification and IOL implantation surgery at Beijing Tongren Eye Center between June 2014 and June 2022. Main medical records included best-corrected visual acuity (BCVA), intraocular pressure (IOP), number of antiglaucoma medications (AGM), corneal status and further surgical interventions. Surgical success was defined as a postoperative IOP ≥ 6mmHg and ≤ 21mmHg without (complete success) or with/without (qualified success) topical AGM and vision of at least light perception during the follow-up period.
Twelve eyes of twelve patients were reviewed. Preoperative IOP was decreased from a mean of 38.5 ± 6.7 mmHg on 3.3 ± 0.9 AGM to a mean of 16.3 ± 4.3 mmHg (P<0.001) on 0.6 ± 1.1 medications (P<0.001) at the last follow-up (47.0 ± 24.7 months). Eight eyes (66.7%) had stable vision or at least one line improvement than that before surgery. Eight eyes (66.7%) achieved qualified success and six eyes (50.0%) achieved complete success after surgery. The surgical procedure had a qualified survival of 91.7% at 1 year, 82.5% at 3 years, 72.2% at 5 years, and 48.1% at 7 years.
AGV implantation combined with phacoemulsification and IOL implantation seems to be an effective method in IOP control and vision maintain for patients with GS-ICE. The combined surgical procedure may be a reliable option for those GS-ICE patients with coexisting cataract.
评估虹膜角膜内皮综合征(GS-ICE)继发青光眼患者行 Ahmed 青光眼引流阀(AGV)植入联合白内障超声乳化吸除及人工晶状体(IOL)植入术后的长期疗效。
本研究为回顾性非对照病例系列研究,2014 年 6 月至 2022 年 6 月,12 例(12 眼)难治性 GS-ICE 合并白内障患者于北京同仁医院行 Ahmed 房水引流阀联合白内障超声乳化吸除及 IOL 植入术。主要观察指标包括最佳矫正视力(BCVA)、眼压(IOP)、降眼压药物(AGM)种类、角膜内皮状态及是否行进一步手术干预。手术成功定义为术后 IOP 为 6~21mmHg,无需(完全成功)或需(部分成功)使用降眼压药物且随访期内视力至少达到光感。
共纳入 12 例(12 眼)患者,术前 IOP 为(38.5±6.7)mmHg,需(3.3±0.9)种 AGM 控制眼压;术后 IOP 为(16.3±4.3)mmHg,需(0.6±1.1)种 AGM 控制眼压,术后 IOP 较术前明显降低(P<0.001)。末次随访时,8 眼(66.7%)视力较术前稳定或提高至少 1 行。8 眼(66.7%)获得部分成功,6 眼(50.0%)获得完全成功。术后 1 年、3 年、5 年和 7 年的手术成功率分别为 91.7%、82.5%、72.2%和 48.1%。
AGV 植入联合白内障超声乳化吸除及 IOL 植入术是治疗 GS-ICE 继发青光眼的有效方法,可有效控制眼压,维持视功能。该联合术式对于合并白内障的 GS-ICE 患者是一种可靠的选择。